Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Wu 6-marker phage peptide panel for Lung Cancer

Wu 6-marker phage peptide panel for Lung Cancer


This biomarker is also known as:

View in BioMuta


The six-phage peptide detector stands out as a promising diagnostic biomarker for NSCLC. The peptide panel could be used to diagnose non-small cell lung cancer and to differentiate between non-small cell lung cancer and chronic obstructive pulmonary diseases. One of the six phage peptides shows 100% homology to olfactomedin 1


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Curated


The sixÃÆ'¢â‚¬â€œphage peptide detector could be used to diagnose NSCLC at early stage and discriminate NSCLC and chronic obstructive pulmonary diseases. Chemotherapy significantly reduced the seroreactivity of the sixÃÆ'¢â‚¬â€œphage peptide clones. The sixÃÆ'¢â‚¬â€œphage peptide detector can be used as a novel method for noninvasive diagnosis and screening of NSCLC in high-risk populations. However, it is unlikely to be used as biomarkers for indicating the relapse of NSCLC after chemotherapy.

Performance Comment

The six-phage peptide detector was able to discriminate between NSCLC patients and healthy controls with a sensitivity and specificity of >92%, and had similar validity for indicating NSCLC at early stage. The seroreactivity of the six phage peptides was significantly higher in the NSCLC patients than in those with chemotherapy and the COPD patients, respectively.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.


No associated resources found.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014

Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.